Clinical Trial Search

Primary: Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)…

Primary: Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8 — 92.9; 84.6 percentage of participants — p=<0.0001

Primary: Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab — 25.2; 49.8; 20.1; 46.1 Milligrams per Liter (mg/L)

Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77

Primary: Percentage of Participants With Mean Hb Value ≥10 g/dL — 83.7 percentage of participants

Primary: Summary of 28-day Seizure Frequency for Major Motor Seizure Types — 49.17; 54.00; 55.50; 45.03 Seizures per day

Primary: Absolute Change in Lung Clearance Index 2.5 (LCI2.5) — -0.02; -2.29 index — p=<0.0001

Primary: Number of Participants With Adjudicated Bleeding Events Within the Main Treatment Period — 1; 1; 0; 0 Participants

Primary: Progression-free Survival (PFS) — 52.9; 80.6 months — p=0.011

Primary: Seroconversion Rate — 47; 46 Participants — p=1

Primary: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population — 264; 258 Participants

Primary: Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination — 204; 0; 59; 0 Participants

Primary: Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12 — -2.1; -4.8; -5.3 days/month — p=<0.0001

Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 73.6; 0 percentage of subjects

Primary: Bacterial Reduction - Groin — 4.133; 3.642; 1.277 log 10 CFU/cm2